A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer

2012 ◽  
Vol 2012 ◽  
pp. 122-123
Author(s):  
J.T. Thigpen
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Cervical Cancer

A Phase II Trial with Cisplatin-Paclitaxel Cytotoxic Treatment and Concurrent External and Endocavitary Radiation Therapy in Locally Advanced or Recurrent Cervical Cancer

Oncology ◽  
2006 ◽  
Vol 70 (1) ◽  
pp. 19-24 ◽  
Author(s):  
L. Miglietta ◽  
P. Franzone ◽  
M.G. Centurioni ◽  
L. Boni ◽  
L. Tacchini ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Radiation Therapy ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Recurrent Cervical Cancer ◽  
Cytotoxic Treatment

A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer

2012 ◽  
Vol 125 (2) ◽  
pp. 307-311 ◽  
Author(s):  
Ryo Kitagawa ◽  
Noriyuki Katsumata ◽  
Masashi Ando ◽  
Chikako Shimizu ◽  
Yasuhiro Fujiwara ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Cervical Cancer

Phase II trial of paclitaxel, 13-cis retinoic acid, and interferon-alfa-2b in the treatment of advanced stage or recurrent cervical cancer

2014 ◽  
Vol 133 ◽  
pp. 29
Author(s):  
M. Song ◽  
R. Di Paola ◽  
B.M. Cracchiolo ◽  
D.G. Gibbon ◽  
M. Hellmann ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Retinoic Acid ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Interferon Alfa ◽  
Advanced Stage ◽  
Recurrent Cervical Cancer

scholarly journals Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

2009 ◽  
Vol 27 (7) ◽  
pp. 1069-1074 ◽  
Author(s):  
Bradley J. Monk ◽  
Michael W. Sill ◽  
Robert A. Burger ◽  
Heidi J. Gray ◽  
Thomas E. Buekers ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Vascular Endothelial ◽  
Oncology Group ◽  
Recurrent Cervical Cancer ◽  
Endothelial Growth Factor

Purpose Vascular endothelial growth factor is a key promoter of tumor progression in cervical carcinoma. The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of bevacizumab, a recombinant humanized anti–vascular endothelial growth factor monoclonal antibody. Patients and Methods Eligible patients had recurrent cervical cancer, measurable disease, and GOG performance status ≤ 2. Treatment consisted of bevacizumab 15 mg/kg intravenously every 21 days until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and toxicity. Results Forty-six patients were enrolled (median age, 46 years); 38 patients (82.6%) received prior radiation as well as either one (n = 34, 73.9%) or two (n = 12, 26.1%) prior cytotoxic regimens for recurrent disease. Grade 3 or 4 adverse events at least possibly related to bevacizumab included hypertension (n = 7), thrombo-embolism (n = 5), GI (n = 4), anemia (n = 2), other cardiovascular (n = 2), vaginal bleeding (n = 1), neutropenia (n = 1), and fistula (n = 1). One grade 5 infection was observed. Eleven patients (23.9%; two-sided 90% CI, 14% to 37%) survived progression free for at least 6 months, and five patients (10.9%; two-sided 90% CI, 4% to 22%) had partial responses. The median response duration was 6.21 months (range, 2.83 to 8.28 months). The median PFS and overall survival times were 3.40 months (95% CI, 2.53 to 4.53 months) and 7.29 months (95% CI, 6.11 to 10.41 months), respectively. This compared favorably with historical phase II GOG trials in this setting. Conclusion Bevacizumab seems to be well tolerated and active in the second- and third-line treatment of patients with recurrent cervical cancer and merits phase III investigation.

Abstract CT142: A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer

2017 ◽  
Author(s):  
Ursula A. Matulonis ◽  
Alexi Wright ◽  
Susana Campos ◽  
Panagiotis Konstantinopoulos ◽  
Ariana Peralta ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Single Stage ◽  
Recurrent Cervical Cancer

Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer

2019 ◽  
Vol 154 (3) ◽  
pp. 554-557 ◽  
Author(s):  
Kazuhiro Suzuki ◽  
Shoji Nagao ◽  
Takashi Shibutani ◽  
Kasumi Yamamoto ◽  
Tomoatsu Jimi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Cervical Cancer

Phase II trial of eribulin in advanced/recurrent cervical cancer

2021 ◽  
Vol 162 ◽  
pp. S69-S70
Author(s):  
Jocelyn Garcia-Sayre ◽  
Yvonne Lin ◽  
Koji Matsuo ◽  
Denice Tsao-Wei ◽  
Paulette Mhawech-Fauceglia ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Cervical Cancer

A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS5618-TPS5618 ◽  
Author(s):  
Ursula Matulonis ◽  
Alexi A. Wright ◽  
Siobhan A Collins ◽  
Susana M. Campos ◽  
Panagiotis Konstantinopoulos ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Single Stage ◽  
Recurrent Cervical Cancer

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer

2019 ◽  
Vol 154 (1) ◽  
pp. 95-101 ◽  
Author(s):  
Joyce F. Liu ◽  
Kathryn P. Gray ◽  
Alexi A. Wright ◽  
Susana Campos ◽  
Panagiotis A. Konstantinopoulos ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Single Stage ◽  
Recurrent Cervical Cancer
Sign in / Sign up

Export Citation Format

Share Document